At a Glance: Retatrutide + CBD Oil
Interaction Summary| Parameter | Detail |
|---|---|
| GLP-1 Medication | Retatrutide — brand names: No brand name assigned (Phase 3 clinical trials as of June 2026) |
| Drug Class | GLP-1/GIP/Glucagon triple receptor agonist (investigational) |
| Approval Status | Not FDA-approved as of June 2026 |
| Cannabis Method | CBD Oil — Oral CBD Drops, Softgels, High-CBD Tinctures |
| Absorption Route | GI tract → liver (oral softgels/capsules); partial sublingual (drops held under tongue) |
| Normal Onset | 30–90 minutes (oral); 15–45 min (sublingual hold) |
| Onset on GLP-1 | Oral: delayed 2–4+ hours on GLP-1; sublingual component less affected |
| GLP-1 Interaction Risk | 🔵 Moderate — Moderate — GI delay + downstream CYP interaction with co-medications |
| Primary Mechanism | GLP-1 gastric emptying delay does not affect pulmonary absorption; pharmacodynamic effects still apply |
The Mechanism: Why Retatrutide Affects CBD Oil Differently
Clinical PharmacologyGLP-1 delays CBD oil absorption — and CBD raises levels of co-medications
Oral CBD oil products — swallowed drops, softgels, capsules — are absorbed through the GI tract and processed by the liver. GLP-1 gastric slowing delays this absorption in the same way it delays edibles and other oral cannabis. Additionally, CBD is a potent inhibitor of CYP450 liver enzymes (CYP2C9, CYP2D6, CYP3A4). While the GLP-1 medication itself is generally not significantly CYP-metabolized, the other medications commonly taken alongside GLP-1 therapy — statins, blood pressure drugs, antidepressants — often are. CBD oil does not merely interact with the GLP-1 drug; it interacts with the entire medication stack. FDA No brand name assigned (Phase 3 clinical trials as of June 2026) PI NIH NCCIH
For Rybelsus or Foundayo patients: oral CBD oil taken near the GLP-1 medication's dosing window competes with it in the GI tract. Rybelsus requires an empty stomach and only 4 oz water for 30 minutes before eating. Foundayo has similar fasting requirements. Take oral CBD at a clearly separate time from these oral GLP-1 medications.
Retatrutide (No brand name assigned (Phase 3 clinical trials as of June 2026)) activates GLP-1 receptors in the gut and brainstem, slowing the rate at which the stomach empties its contents into the small intestine. This mechanism is intentional and contributes to the medication's appetite-suppressing effects and post-meal blood glucose control. For inhaled cannabis, this mechanism is irrelevant because lung absorption bypasses the GI tract entirely. FDA No brand name assigned (Phase 3 clinical trials as of June 2026) PI
CBD affects co-medications taken alongside GLP-1 therapy
The most clinically significant CBD oil concern in GLP-1 patients is not the CBD-GLP-1 interaction itself — it is CBD's effect on the other drugs in the same patient's medication regimen. A patient on Ozempic, atorvastatin, lisinopril, and sertraline who adds daily CBD oil is introducing CYP enzyme inhibition that may raise levels of all three co-medications simultaneously. This is the context in which CBD oil review with a pharmacist or prescriber is most important.
About Retatrutide: Drug Profile
Medication Context| Detail | Information |
|---|---|
| Generic Name | Retatrutide |
| Brand Names | No brand name assigned (Phase 3 clinical trials as of June 2026) |
| Drug Class | GLP-1/GIP/Glucagon triple receptor agonist (investigational) |
| Approved Uses | Obesity and type 2 diabetes (investigational — not FDA-approved) |
| Administration | Injectable once-weekly subcutaneous (investigational) |
| Approval Status | Not FDA-approved as of June 2026 |
As a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide is expected to produce gastric slowing at least equivalent to — and potentially exceeding — tirzepatide (dual agonist) and semaglutide (single agonist). Oral cannabis absorption delays are predicted to apply on mechanistic grounds, though clinical pharmacokinetic data in retatrutide patients is not yet available.
Practical Guidance for Retatrutide Patients Using CBD Oil
Clinical Recommendations- GLP-1 gastric slowing delays oral CBD oil absorption — therapeutic effect takes longer and may be less predictable
- CBD inhibits CYP3A4, CYP2C9, and CYP2D6 — review all co-medications for interaction risk at interactsafe.com
- For Rybelsus or Foundayo: take oral CBD at a separate time from the oral GLP-1 to avoid GI timing conflict
- CBD softgels and capsules behave identically to edibles from a GLP-1 gastric slowing standpoint
- Sublingual CBD oil (held 60–90 sec) provides faster and more predictable onset than swallowed CBD on GLP-1 medications
Frequently Asked Questions
Retatrutide + CBD Oil CannabisCan I take CBD oil while on Retatrutide (No brand name assigned (Phase 3 clinical trials as of June 2026))? ▼
CBD oil can be used alongside Retatrutide (No brand name assigned (Phase 3 clinical trials as of June 2026)), but requires awareness of two separate concerns. First, Retatrutide's gastric slowing delays oral CBD oil absorption — therapeutic effect arrives later and less predictably than without GLP-1 medication. Second, CBD inhibits CYP450 liver enzymes (CYP2C9, CYP2D6, CYP3A4), which may raise plasma levels of other medications you take alongside Retatrutide — particularly statins, blood pressure drugs, and antidepressants. Use the InteractSafe checker to review your complete medication list for CBD interactions.
Does CBD oil interact with No brand name assigned (Phase 3 clinical trials as of June 2026)? ▼
The direct pharmacokinetic interaction between CBD and Retatrutide (No brand name assigned (Phase 3 clinical trials as of June 2026)) is generally low — GLP-1 receptor agonists are not primarily CYP-metabolized, so CBD enzyme inhibition does not significantly raise Retatrutide drug levels. The more relevant interaction is pharmacodynamic and contextual: Retatrutide's gastric slowing delays CBD absorption, and CBD's CYP inhibition affects other medications in the same patient's regimen. For patients on Retatrutide who also take warfarin, statins, or antidepressants, CBD oil creates a downstream interaction concern with those co-medications.
How should I time CBD oil doses with Retatrutide? ▼
Timing CBD oil with Retatrutide (No brand name assigned (Phase 3 clinical trials as of June 2026)) depends on the form. For injectable GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, Saxenda, Byetta, Bydureon), CBD oil timing does not need to be coordinated with the injection, but the CBD oil's own absorption will be delayed by Retatrutide's gastric slowing regardless of when it is taken. For oral GLP-1 medications (Rybelsus, Foundayo), take CBD oil at a clearly separate time — these oral GLP-1 pills have strict fasting requirements that oral CBD oil conflicts with. Morning GLP-1, evening CBD oil, for example.
View credentials → · Verify NPI →
Primary Sources
- NIH NCCIH. "Cannabis (Marijuana) and Cannabinoids: What You Need To Know." Updated December 2021. Drug interactions and cannabis pharmacokinetics by route of administration.
https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know - FDA. Epidiolex (cannabidiol) Prescribing Information. NDA 210365. CYP2C9, CYP2D6, CYP3A4 inhibition by CBD — relevant to co-medications taken alongside GLP-1 therapy.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210365s006lbl.pdf - NIH MedlinePlus. Retatrutide Drug Information. National Library of Medicine. Pharmacodynamics, gastric emptying, and drug interaction sections.
https://medlineplus.gov/druginformation.html
Check Your Full Medication List
Taking Retatrutide plus other medications or supplements? Use InteractSafe to review your complete combination.
Retatrutide + Cannabis Full Profile →Or open the full interaction checker · Free · No account required · Not medical advice